WO2008086182A3 - Use of gene signatures to design novel cancer treatment regimens - Google Patents

Use of gene signatures to design novel cancer treatment regimens Download PDF

Info

Publication number
WO2008086182A3
WO2008086182A3 PCT/US2008/050237 US2008050237W WO2008086182A3 WO 2008086182 A3 WO2008086182 A3 WO 2008086182A3 US 2008050237 W US2008050237 W US 2008050237W WO 2008086182 A3 WO2008086182 A3 WO 2008086182A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer treatment
treatment regimens
gene signatures
novel cancer
design novel
Prior art date
Application number
PCT/US2008/050237
Other languages
French (fr)
Other versions
WO2008086182A2 (en
Inventor
Craig T Jordan
Monica L Guzman
Duane C Hassane
Original Assignee
Univ Rochester
Craig T Jordan
Monica L Guzman
Duane C Hassane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rochester, Craig T Jordan, Monica L Guzman, Duane C Hassane filed Critical Univ Rochester
Publication of WO2008086182A2 publication Critical patent/WO2008086182A2/en
Publication of WO2008086182A3 publication Critical patent/WO2008086182A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Computation (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
  • Bioethics (AREA)
  • Chemical & Material Sciences (AREA)
  • Artificial Intelligence (AREA)
  • Urology & Nephrology (AREA)
  • Databases & Information Systems (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are and methods for identifying treatments for diseases. Also disclosed are compositions for Acute Myeloid Leukemia.
PCT/US2008/050237 2007-01-04 2008-01-04 Use of gene signatures to design novel cancer treatment regimens WO2008086182A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88334107P 2007-01-04 2007-01-04
US60/883,341 2007-01-04

Publications (2)

Publication Number Publication Date
WO2008086182A2 WO2008086182A2 (en) 2008-07-17
WO2008086182A3 true WO2008086182A3 (en) 2008-12-11

Family

ID=39609321

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/050237 WO2008086182A2 (en) 2007-01-04 2008-01-04 Use of gene signatures to design novel cancer treatment regimens

Country Status (1)

Country Link
WO (1) WO2008086182A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105181976A (en) * 2015-09-29 2015-12-23 武汉大学 Function and application of TRIM8 (tripartite motif 8) inhibitor in inhibition of myocardial hypertrophy

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101054952B1 (en) * 2009-01-22 2011-08-05 재단법인 한국원자력의학원 UCCR, a marker for diagnosing liver cancer and predicting patient survival, a kit including the same, and prediction of liver cancer patient survival using the marker
US8741581B2 (en) 2009-04-27 2014-06-03 Technion Research And Development Foundation Ltd. Markers for cancer detection
WO2012002011A1 (en) * 2010-06-29 2012-01-05 学校法人 久留米大学 Method for predicting therapeutic effect of immunotherapy on cancer patient, and gene set and kit to be used in the method
GB2482187A (en) * 2010-07-23 2012-01-25 Univ Exeter Predicting response to surgery
WO2012021795A2 (en) 2010-08-13 2012-02-16 Somalogic, Inc. Pancreatic cancer biomarkers and uses thereof
WO2012135651A1 (en) 2011-03-31 2012-10-04 The Procter & Gamble Company Systems, models and methods for identifying and evaluating skin-active agents effective for treating dandruff/seborrheic dermatitis
WO2012151277A1 (en) * 2011-05-02 2012-11-08 Applied Informatic Solutions, Inc. Kits and methods for selecting a treatment for ovarian cancer
EP2549399A1 (en) * 2011-07-19 2013-01-23 Koninklijke Philips Electronics N.V. Assessment of Wnt pathway activity using probabilistic modeling of target gene expression
JP2015527630A (en) 2012-06-06 2015-09-17 ザ プロクター アンド ギャンブルカンパニー Cosmetic identification system and method for hair / scalp care composition
US20150252429A1 (en) * 2012-10-31 2015-09-10 Nathan D. Price Detection of brain cancer types
US20160010059A1 (en) * 2013-03-06 2016-01-14 The Regents Of The University Of California EXPANSION OF HEMATOPOIETIC PROGENITOR CELLS BY HISTONE METHYLTRANSFERASE G9a INHIBITION
CN105018576B (en) * 2014-04-18 2020-02-14 烟台聚杰生物工程有限公司 Application of 15 male fertility-related proteins or combination thereof
CN112501298B (en) * 2020-12-07 2022-04-01 北京起源聚禾生物科技有限公司 Composition and kit for methylation noninvasive early detection of ovarian cancer
WO2024052496A1 (en) 2022-09-07 2024-03-14 Universite Catholique De Louvain Transferin receptor detection for calr mutant positive myeloproliferative neoplasms screening

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461807B1 (en) * 1997-02-28 2002-10-08 Fred Hutchinson Cancer Research Center Methods for drug target screening

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461807B1 (en) * 1997-02-28 2002-10-08 Fred Hutchinson Cancer Research Center Methods for drug target screening

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DICK: "Acute Myeloid Leukemia Stem Cells", ANNALS OF THE NEW YORK ACADEMY OF SCIENCE, vol. 1044, 2005, pages 1 - 5 *
GOLUB ET AL.: "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring", SCIENCE, vol. 286, October 1999 (1999-10-01), pages 531 - 537, XP002207658 *
HONG ET AL.: "RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis", BIOINFORMATICS, vol. 22, no. 22, 2006, pages 2825 - 2827 *
LAMB ET AL.: "The connectivity MAP: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease", SCIENCE, vol. 313, September 2006 (2006-09-01), pages 1929 - 1935, XP002519100, DOI: doi:10.1126/science.1132939 *
SEO ET AL.: "Platelet-Activating Factor Induces Up-regulation of Antiapoptotic Factors in a Melanoma Cell Line through Nuclear Factor-kappa B Activation", CANCER RESEARCH, vol. 66, no. 9, May 2006 (2006-05-01), pages 4681 - 4686 *
SHAPIRA ET AL.: "The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells", BREAST CANCER RESEARCH, vol. 8, 2006, pages R46, XP021020741 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105181976A (en) * 2015-09-29 2015-12-23 武汉大学 Function and application of TRIM8 (tripartite motif 8) inhibitor in inhibition of myocardial hypertrophy

Also Published As

Publication number Publication date
WO2008086182A2 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
WO2008086182A3 (en) Use of gene signatures to design novel cancer treatment regimens
HRP20160949T1 (en) Novel compositions and methods for cancer treatment
EP2125855A4 (en) Methods and compositions for the treatment of cancer or other diseases
WO2008076278A3 (en) Methods of cancer treatment with igf1r inhibitors
EP2249644A4 (en) Picoplatin and amrubicin to treat lung cancer
WO2008134761A3 (en) Modification of biological targeting groups for the treatment of cancer
WO2010062863A3 (en) Compositions containing satiogens and methods of use
WO2010019271A8 (en) Fluorescent regulators of rassf1a expression and human cancer cell proliferation
EP1991701A4 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
WO2005116259A3 (en) Use of gene expression profiling to predict survival in cancer patient
MX2009003362A (en) Use of pegylated il-10 to treat cancer.
MX2014008640A (en) Pharmaceutical compositions and methods.
WO2007081751A9 (en) Compositions and methods for the treatment of cancer
WO2011041336A3 (en) Treating notch1-antagonist-resistant cancer (s) using notch3 antagonists
EP4285911A3 (en) Methods and compositions for diagnosis and treatment of cancer
WO2009114703A3 (en) Combination therapy for the treatment of cancer
EP2329044A4 (en) Prmt1 for target genes of cancer therapy and diagnosis
WO2012006181A3 (en) Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
WO2008112290A3 (en) Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
WO2012061390A3 (en) Therapeutic compositions and methods
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
WO2008144507A3 (en) Spirooxindole inhibitors of aurora kinase
WO2008051523A3 (en) Carbazole derivatives useful as medicaments in cancer therapy
EP2164990A4 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
EP2170351A4 (en) Methods and compositions for treatment of cancer and other angiogenesis - related diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08705686

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08705686

Country of ref document: EP

Kind code of ref document: A2